Clinical Trial Update: Docetaxel With or Without Ascorbic Acid in Treating Patients With Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel with or without ascorbic acid in metastatic, hormone-resistant prostate cancer has terminated; results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Ascorbic acid (Vitamin C)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2022-08-08